Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Alzheimer's Disease

Free Subscription 22.06.2026 3 Acta Neuropathol 2 Alzheimer Dis Assoc Disord 15 Alzheimers Dement 1 Am J Geriatr Psychiatry 1 BMC Neurol 2 Curr Alzheimer Res 22 J Alzheimers Dis 2 J Neurol Neurosurg Psychiatry 1 N Engl J Med 3 Nat Med 1 Nat Rev Neurol 1 Neurobiol Aging 1 Neurobiol Dis 4 Neurology 1 Neurosci Lett 1 Neuroscience 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Neuropathol

1. SEIFFER S, Rotter J, Brendler J, Ricken A, et al
   Expression of GPR34 in microglia remains stable in human Alzheimer's disease.
   Acta Neuropathol. 2026;151:66.
   PubMed         Abstract available
   
   
2. FANCY NN, Willumsen N, Chau VMN, Boulger SL, et al
   Mechanisms of increased Alzheimer's disease pathology with R47H and R62H TREM2 variants.
   Acta Neuropathol. 2026;151:67.
   PubMed         Abstract available
   
   
3. WELIKOVITCH LA, Oakley DH, Bennett RE, Serrano-Pozo A, et al
   Neuropathological study of the effects of aducanumab anti-Abeta immunotherapy on patients with Alzheimer's disease.
   Acta Neuropathol. 2026;151:68.
   PubMed         Abstract available
   
   

   
   Alzheimer Dis Assoc Disord

4. JACOBSEN E, Zhang Y, Ganguli M, Chang CH, et al
   Olfaction, Cognition, and Early Signs of Neurodegenerative Disease in a Community-Based Sample of Older Adults.
   Alzheimer Dis Assoc Disord. 2026;40:85-92.
   PubMed         Abstract available
   
   
5. HILSABECK RC, Santiago-Mejias S, Fletcher TL, Rhodes SL, et al
   Detecting Cognitive Impairment Early in Hispanic and Black Older Adults: Community Voices From South Central Texas.
   Alzheimer Dis Assoc Disord. 2026;40:157-161.
   PubMed         Abstract available
   
   

   
   Alzheimers Dement

6. MAROLA OJ, Uyar A, Keezer KJ, Chong Chie JAK, et al
   WSB.APP/PS1 mice develop age-dependent cerebral amyloid angiopathy, cerebrovascular dysfunction, and white matter deficits.
   Alzheimers Dement. 2026;22:e71476.
   PubMed         Abstract available
   
   
7. MUNDADA NS, Sadeghpour N, McGrew E, Tucker HL, et al
   Vulnerability of anterior medial temporal lobe subregions to early tau-related neurodegeneration in Alzheimer's disease: Converging evidence from tau-PET and plasma p-tau217.
   Alzheimers Dement. 2026;22:e71571.
   PubMed         Abstract available
   
   
8. VEITCH DP, Miller MJ, Kanoria S, Aisen PS, et al
   Contributions of the Alzheimer's Disease Neuroimaging Initiative to advancing AD research: a targeted review of recent publications.
   Alzheimers Dement. 2026;22:e71566.
   PubMed         Abstract available
   
   
9. AGRAWAL S, Yu L, Leurgans SE, Li J, et al
   Hippocampal GFAP in aging: Associations with AD and LATE-NC pathologies and cognitive decline in older adults.
   Alzheimers Dement. 2026;22:e71613.
   PubMed         Abstract available
   
   
10. ASSFAW AD, Xiong C, Moulder KL, Morris JC, et al
    Evaluating the accuracy and reliability of telephone-derived Clinical Dementia Rating scores: A comparative analysis with in-person assessments.
    Alzheimers Dement. 2026;22:e71601.
    PubMed         Abstract available
    
    
11. LEE M, Meylan S, Shobin E, Nisenbaum L, et al
    Digital speech-based markers to advance prognosis in Alzheimer's disease.
    Alzheimers Dement. 2026;22:e71489.
    PubMed         Abstract available
    
    
12. CALLOW DD, Rani N, Smith JC, Soldan A, et al
    APOE epsilon4 and amyloid status moderate the associations between sleep, physical activity, and tau-PET burden in cognitively unimpaired older adults.
    Alzheimers Dement. 2026;22:e71555.
    PubMed         Abstract available
    
    
13. PARDO E, Kim T, Wallrabe H, Zengeler KE, et al
    Mitochondrial NADK2-dependent NADPH controls tau oligomer uptake in human neurons.
    Alzheimers Dement. 2026;22:e71594.
    PubMed         Abstract available
    
    
14. SHANKS HRC, Chen S, Onuska KM, Schmitz TW, et al
    A lifespan staging model of basal forebrain cholinergic vulnerability.
    Alzheimers Dement. 2026;22:e71380.
    PubMed         Abstract available
    
    
15. ANDRADE V, Kleineidam L, Wagner-Thelen H, Ballarini T, et al
    Prediction of cognitive outcome and progression to dementia using omega6-PUFA/omega3-PUFA ratio.
    Alzheimers Dement. 2026;22:e71590.
    PubMed         Abstract available
    
    
16. RAKET LL, Lu M, Evans CD, Zimmer JA, et al
    Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial.
    Alzheimers Dement. 2026;22:e71577.
    PubMed         Abstract available
    
    
17. COTTEZ RJ, Peyrot C, Denis HL, Tremblay C, et al
    Plasma p-tau markers, vascular factors, and cognitive decline in the CIMA-Q cohort.
    Alzheimers Dement. 2026;22:e71588.
    PubMed         Abstract available
    
    
18. GUO Y, Wang R, Sindi S, Middleton LT, et al
    Sleep and dementia: Assessing established dementia-related factors using multivariable Mendelian randomization.
    Alzheimers Dement. 2026;22:e71592.
    PubMed         Abstract available
    
    
19. AMOUYEL P, Andrieu S, Bradshaw A, Carmona RC, et al
    Provider and patient perspectives on the diagnosis and treatment of Alzheimer's disease: A global perspective from the Global Alzheimer's Leadership Series (GoALS).
    Alzheimers Dement. 2026;22:e71536.
    PubMed         Abstract available
    
    
20. SIENGSUKON CF, Hand LK, Nelson E, Glaser A, et al
    The impact of cognitive behavioral therapy for insomnia on cognitive performance and amyloid beta in older adults: A randomized controlled trial.
    Alzheimers Dement. 2026;22:e71591.
    PubMed         Abstract available
    
    

    
    Am J Geriatr Psychiatry

21. DA SILVA AMP, de Siqueira Lima DV Jr, Figueiroa Souza R, Lopes VHP, et al
    Cannabinoids Treatment for Agitation in Alzheimer's Disease: A Systematic Review and Meta-Analysis With Bayesian and Sequential Trial Analyses.
    Am J Geriatr Psychiatry. 2026 May 29:S1064-7481(26)00400.
    PubMed         Abstract available
    
    

    
    BMC Neurol

22. JAVED A, Kumar S, Iftekhar M, Siddiqui HT, et al
    Trends in both Alzheimer's disease and Diabetes mellitus related mortality among middle-aged and older adults in the United States, 1999 to 2023: a CDC WONDER database analysis.
    BMC Neurol. 2026 Jun 12. doi: 10.1186/s12883-026-05058.
    PubMed         Abstract available
    
    

    
    Curr Alzheimer Res

23. SAEB L, Abtahi S, Masoudi R, Javadpour A, et al
    Association of Polymorphisms in Genes Involved in Serotonergic Signaling with the Risk of Developing Alzheimer's Disease.
    Curr Alzheimer Res. 2026 Jun 18. doi: 10.2174/0115672050459074260331053012.
    PubMed         Abstract available
    
    
24. IMAI N, Yano H, Ikegame Y, Yasuda S, et al
    Cerebral Hyperperfusion with Lecanemab in Alzheimer's Disease Assessed by Amyloid PET and Arterial Spin Labeling.
    Curr Alzheimer Res. 2026 Apr 24. doi: 10.2174/0115672050453079260226065149.
    PubMed         Abstract available
    
    

    
    J Alzheimers Dis

25. YANG L, Zeng J, Huang L, Li L, et al
    The evolving burden of early-onset Alzheimer's disease and other dementias in BRICS countries: Insights from the Global Burden of Disease Study 2023 and projections to 2035.
    J Alzheimers Dis. 2026 Jun 18:13872877261460745. doi: 10.1177/13872877261460745.
    PubMed         Abstract available
    
    
26. NAKASHIMA S, Sato K, Niimi Y, Aso S, et al
    Early adoption of lecanemab in Japan (December 2023-December 2024): Pretreatment diagnostic timelines from the DeSC claims database.
    J Alzheimers Dis. 2026;111:1510-1515.
    PubMed         Abstract available
    
    
27. SONG JH, Kim HJ, Son M, Kim HR, et al
    The association between hemoglobin level and risk of developing dementia.
    J Alzheimers Dis. 2026;111:1614-1624.
    PubMed         Abstract available
    
    
28. PECK MR, Chapman JE, Hill T, Quinn K, et al
    D-methionine improves spatial navigation and attenuates oxidative stress and amyloid pathology in a sex-specific manner.
    J Alzheimers Dis. 2026;111:1807-1819.
    PubMed         Abstract available
    
    
29. PELOSO GM, Wang D, Abbruzzese SM, Bis JC, et al
    Whole genome sequencing analysis of over 3500 individuals dementia-free over 85 years old.
    J Alzheimers Dis. 2026;111:1772-1782.
    PubMed         Abstract available
    
    
30. SMITH AN, Burns JM, Sullivan DK, Morris JK, et al
    Larger baseline body stature predicts one-year amyloid change in cognitively normal older adults enriched with elevated amyloid status.
    J Alzheimers Dis. 2026;111:1881-1891.
    PubMed         Abstract available
    
    
31. CHIU WH, Kang MJY, Goh AMY, Velakoulis D, et al
    Systematic review and meta-analysis of associations between neuropsychiatric symptoms and amyloid, tau, neuronal, and glial biomarkers in young-onset dementias.
    J Alzheimers Dis. 2026;111:1439-1458.
    PubMed         Abstract available
    
    
32. FUJIWARA Y, Toyoda K, Maruyama S, Kitano M, et al
    Dementia screening with the Rivermead Behavioural Memory Test: A machine learning analysis.
    J Alzheimers Dis. 2026;111:1601-1613.
    PubMed         Abstract available
    
    
33. DIEGUEZ FERREIRA Y, Braga Moura C, Carneiro Rodrigues A, Pereira Da Silva AM, et al
    Causes of death in patients with dementia: A study in a geriatric hospital in Sao Paulo, Brazil.
    J Alzheimers Dis. 2026;111:1735-1741.
    PubMed         Abstract available
    
    
34. PULIDO-CORREA VE, Hernandez AV, Wind EJ, Zhu Y, et al
    Ketogenic diet enhances cognitive-behavioral function and hippocampal neurogenesis while attenuating amyloid pathology in Tg-SwDI mice.
    J Alzheimers Dis. 2026;111:1563-1586.
    PubMed         Abstract available
    
    
35. AHMED ABBASI A, Norouziyan F, Moradikor N
    Role of suvorexant in Alzheimer's disease: Targeting sleep, orexin signaling, and disease pathophysiology.
    J Alzheimers Dis. 2026 Jun 18:13872877261461161. doi: 10.1177/13872877261461161.
    PubMed         Abstract available
    
    
36. DRZAZGA J, Segiet-Hojda NM, Poczatek G, Gorzkowska A, et al
    Narratives about the reasons for wandering in people with Alzheimer's disease: The perspective of Polish family members. Preliminary report.
    J Alzheimers Dis. 2026 Jun 17:13872877261459071. doi: 10.1177/13872877261459071.
    PubMed         Abstract available
    
    
37. WANG X, Zhang W, He J, Zhang X, et al
    Adverse events of Alzheimer's disease patients treated with memantine-based therapies: A disproportionality analysis of the FAERS database based on the MY FAERS platform.
    J Alzheimers Dis. 2026 Jun 16:13872877261458818. doi: 10.1177/13872877261458818.
    PubMed         Abstract available
    
    
38. BALOHE M, Thivet J, Blanc F, Krein L, et al
    Language and communication disorders in dementia with Lewy bodies versus Alzheimer's disease: Objective screening and subjective perspectives of patients, their caregivers and clinicians.
    J Alzheimers Dis. 2026 Jun 16:13872877261458679. doi: 10.1177/13872877261458679.
    PubMed         Abstract available
    
    
39. DECONNE TM, Suerken CK, Lipford ME, Lockhart SN, et al
    Structural and load-dependent arterial stiffness are differentially associated with cognition or biomarkers of Alzheimer's disease and related dementias: The healthy brain study.
    J Alzheimers Dis. 2026 Jun 16:13872877261458779. doi: 10.1177/13872877261458779.
    PubMed         Abstract available
    
    
40. SELMANOVIC E, Gibbons LE, Folkerth RD, Keene CD, et al
    Traumatic brain injury and late-life Alzheimer's disease neuropathology: Quantitative investigation in the Adult Changes in Thought study.
    J Alzheimers Dis. 2026 Jun 16:13872877261457138. doi: 10.1177/13872877261457138.
    PubMed         Abstract available
    
    
41. RODRIGUES AC, Valerio FG, Moura CB, Da Silva AMP, et al
    Impacts of menopausal hormone therapy on Alzheimer's disease biomarkers: A systematic review.
    J Alzheimers Dis. 2026 Jun 16:13872877261456766. doi: 10.1177/13872877261456766.
    PubMed         Abstract available
    
    
42. CHURCHILL N, Le TT, Nianogo RA
    Alzheimer's disease and related dementias state policies and mortality in the United States: A descriptive study.
    J Alzheimers Dis. 2026 Jun 16:13872877261453609. doi: 10.1177/13872877261453609.
    PubMed         Abstract available
    
    
43. BEH-PAJOOH A
    Identification of candidate diagnostic biomarkers and gene networks for moderate stages of Alzheimer's disease in fusiform gyrus exhibiting neurofibrillary tangles.
    J Alzheimers Dis. 2026 Jun 16:13872877261452277. doi: 10.1177/13872877261452277.
    PubMed         Abstract available
    
    
44. LEEM S, Yang Y, Woods AJ, Fang R, et al
    Prediction of Alzheimer's disease risk factors from retinal images via deep learning: Development and validation of biologically relevant morphological associations in the UK Biobank.
    J Alzheimers Dis. 2026 Jun 16:13872877261457650. doi: 10.1177/13872877261457650.
    PubMed         Abstract available
    
    
45. EVERS MJAP, Krom BP, de Jongh CA
    A mechanistic framework linking the oral microbiome to Alzheimer's disease through neuroinflammation.
    J Alzheimers Dis. 2026 Jun 12:13872877261456324. doi: 10.1177/13872877261456324.
    PubMed         Abstract available
    
    
46. KERET O, Xia T, Wilkins S, Ncube LNL, et al
    Real-world clinical profile of individuals with cerebrospinal fluid Abeta(-)/pTau181().
    J Alzheimers Dis. 2026;111:1872-1880.
    PubMed         Abstract available
    
    

    
    J Neurol Neurosurg Psychiatry

47. 
    Correction: How well do plasma Alzheimer's disease biomarkers reflect the CSF amyloid status?
    J Neurol Neurosurg Psychiatry. 2026;97:e1.
    PubMed        
    
    
48. 
    Correction: First presentation with neuropsychiatric symptoms in autosomal dominant Alzheimer's disease: the Dominantly Inherited Alzheimer's Network Study.
    J Neurol Neurosurg Psychiatry. 2026;97:e2.
    PubMed        
    
    

    
    N Engl J Med

49. RAFII MS
    The Convergence of Down Syndrome and Alzheimer's Disease - Scientific and Ethical Imperatives.
    N Engl J Med. 2026;394:2286-2289.
    PubMed        
    
    

    
    Nat Med

50. HONEY MIJ, Hok-A-Hin YS, Thijssen EH, Cousins KAQ, et al
    An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration.
    Nat Med. 2026;32:2083-2095.
    PubMed         Abstract available
    
    
51. LU A, Chen WT, Dalby M, Sainz Garcia D, et al
    Human microglial transitions at the Abeta-tau inflection point associate with divergent pathways to dementia and resilience.
    Nat Med. 2026;32:2047-2059.
    PubMed         Abstract available
    
    
52. DING DY, Bot VA, Chen KL, Groves JW, et al
    Plasma proteomic signatures of cellular aging predict human disease.
    Nat Med. 2026;32:2060-2072.
    PubMed         Abstract available
    
    

    
    Nat Rev Neurol

53. FYFE I
    Autophagy protein links ageing and Alzheimer disease.
    Nat Rev Neurol. 2026 Jun 15. doi: 10.1038/s41582-026-01235.
    PubMed        
    
    

    
    Neurobiol Aging

54. PILLET P, Tremblay-Mercier J, Picard C, Rosa-Neto P, et al
    Oral body temperature and cerebrospinal fluid pTau181 in older adults at increased risk of Alzheimer's disease.
    Neurobiol Aging. 2026;167:25-28.
    PubMed         Abstract available
    
    

    
    Neurobiol Dis

55. SILVA-LLANES I, Baceiredo-Macho P, Lastres-Becker I
    Analysis of the involvement of RNA-binding proteins in TAU-dependent neurodegeneration.
    Neurobiol Dis. 2026;226:107454.
    PubMed         Abstract available
    
    

    
    Neurology

56. CERIELLO C, Torres OH, Rubio-Guerra S, Garcia-Castro J, et al
    Clinical Impact and Prognostic Value of Alzheimer Disease Biomarkers in the Very Old.
    Neurology. 2026;107:e218180.
    PubMed         Abstract available
    
    
57. GANESH A, Smith EE, Mostert J, Strijbis EM, et al
    Phase 2 Futility Trials in Alzheimer Disease and Mild Cognitive Impairment: A Cohort Analysis of the ADNI Data Set.
    Neurology. 2026;107:e218227.
    PubMed         Abstract available
    
    
58. WANG ZY, Xin JW, Wang MY, Chen S, et al
    Clinical Evaluation of the Revised Biological and Clinical Staging Criteria for Alzheimer Disease in China.
    Neurology. 2026;107:e218184.
    PubMed         Abstract available
    
    
59. CASH DM, Knopman DS
    Not Lost in Translation: Universality of Clinical-Pathobiologic Correlation in Alzheimer Disease.
    Neurology. 2026;107:e218262.
    PubMed        
    
    

    
    Neurosci Lett

60. ROY CHOUDHURY R, Kushwaha S, Karunakaran S
    Prolonged beta-adrenergic stimulation reduces beta2-adrenergic receptor levels and limits astrocytic responsiveness during early amyloid pathology.
    Neurosci Lett. 2026;881:138618.
    PubMed         Abstract available
    
    

    
    Neuroscience

61. REN L, Luo XQ, Mi FY, Yu CY, et al
    Current status and challenges in targeting circulating amyloid-beta carriers for Alzheimer's disease therapy.
    Neuroscience. 2026;610:189-197.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

62. DOUGNON G, Otsuka T, Nakamura Y, Sakai A, et al
    A protective role for APP in nuclear waste clearance via lysosomal exocytosis.
    Proc Natl Acad Sci U S A. 2026;123:e2524190123.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum